ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.76 +0.44 (+2.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study ↗

September 24, 2025

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Via Stocktwits

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

September 24, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Technical Setup for Potential Breakout ↗

September 19, 2025

ACADIA Pharmaceuticals (ACAD) shows strong technical momentum with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.

Via Chartmill

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

September 12, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts ↗

September 09, 2025

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Emerges as a Top Affordable Growth Stock ↗

September 08, 2025

ACADIA Pharmaceuticals (ACAD) offers strong growth metrics and a reasonable valuation within the biotech sector, making it a top affordable growth stock pick.

Via Chartmill

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

August 26, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

August 25, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential ↗

August 18, 2025

ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy.

Via Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential ↗

August 16, 2025

ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick.

Via Chartmill

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia (ACAD) Q2 Revenue Rises 9% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates ↗

August 06, 2025

Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month.

Via Chartmill

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

August 06, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

August 04, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation ↗

July 25, 2025

ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech.

Via Chartmill

What Analysts Are Saying About ACADIA Pharmaceuticals Stock ↗

July 24, 2025

Via Benzinga

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

July 23, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential ↗

July 22, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors.

Via Chartmill

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation ↗

July 04, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth...

Via Chartmill

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

June 25, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential ↗

June 24, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities.

Via Chartmill

13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know ↗

June 23, 2025

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.